TA-NIC

TA-NIC is a proprietary, investigational vaccine developed as an aid for smoking cessation. It is designed to induce the production of human anti-nicotine antibodies that bind nicotine in the bloodstream, forming complexes too large to cross the blood-brain barrier. This mechanism reduces or eliminates nicotine’s psychoactive effects by preventing it from reaching nicotinic acetylcholine receptors in the brain, thereby diminishing the rewarding and addictive properties of nicotine and supporting efforts to quit smoking. The vaccine is a protein-based conjugate immunotherapy similar in concept to other anti-drug vaccines such as TA-CD. Clinical development reached Phase 2 trials but was discontinued due to insufficient efficacy[1][2][3][4][5][7].